The use of Ankaferd in diverticular bleeding: Two case reports

Aslan, Ekrem; Akyüz, Ümit; Pata, Cengiz

doi:10.4318/tjg.2013.0640

Cited by 9 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ABS was used as a primary therapy in stopping diverticular bleed within few minutes in two patients, one of them was on warfarin. There was no recurrence of bleeding in both patients after 60 days follow up …”

Section: The Use Of Hemostatic Powders In Lower Gastrointestinal Bleementioning

confidence: 75%

See 1 more Smart Citation

Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review

Mourad

Leong

2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

Despite the recent advances in endoscopic hemostatic techniques, the management of lower gastrointestinal bleeding could be sometimes challenging. Hemostatic powders such as Hemospray, EndoClot, and Ankaferd Blood Stopper have found their way into digestive endoscopy and are licenced in many countries especially for use in upper gastrointestinal bleeding. We reviewed the literature on the use of these hemostatic powders in different situations in lower gastrointestinal bleeding and looked at the success rate and rebleeding rate. Most of the data are derived from case reports, retrospective and prospective case series with absence of any randomized controlled trials. Hemostatic powders were used as primary or salvage therapy to control bleeding from polypectomy site, colonic tumors, diverticula, arteriovenous malformations, radiation proctitis, ischemic colitis, and surgical intestinal anastomosis. The rate of immediate control of bleeding is in the range of 88-100% with a recurrence rate of 3-13% except for radiation proctitis bleeding where rebleeding rate can be as high as 77%. Although there are many advantages for the use of local hemostatic agents in lower gastrointestinal bleeding, future randomized controlled trials comparing them with conventional methods are needed.

show abstract

Section: The Use Of Hemostatic Powders In Lower Gastrointestinal Bleementioning

confidence: 75%

“…There was no recurrence of bleeding in both patients after 60 days follow up. 30 Bleeding from AVMs and other vascular lesions are unusual causes of acute LGIB. Hemospray was successfully used in one case of bleeding from AVM 17 and two patients with Dieulafoy lesions.…”

Section: Available Hemostatic Powdersmentioning

confidence: 99%

Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review

Mourad

Leong

2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…The ABS GI data from published reports with encouraging results proved the safety and efficiency of ABS as a hemostatic agent for distinct states of GI bleeding. ABS is clinically effective in bleeding individuals with normal hemostatic parameters and in patients with deficient primary hemostasis and/or secondary hemostasis [9,12,13,14,15,16,17,18,19,20,21,23,26,27,28,29,30,31,32,33,34,35,36]. ABS may act as a topical biological response modifier as well as having antihemorrhagic actions.…”

Section: Discussionmentioning

confidence: 99%

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

Koluman¹,

Akar²,

Haznedaroğlu³

2017

Tjh

View full text Add to dashboard Cite

Objective:Ankaferd hemostat (Ankaferd Blood Stopper®, ABS)-induced pharmacological modulation of essential erythroid proteins can cause vital erythroid aggregation via acting on fibrinogen gamma. Topical endoscopic ABS application is effective in the controlling of gastrointestinal (GI) system hemorrhages and/or infected GI wounds. Escherichia coli O157:H7, the predominant serotype of enterohemorrhagic E. coli, is a cause of both outbreaks and sporadic cases of hemorrhagic colitis. The aim of this study is to examine the effects of ABS on 6 different Shiga toxigenic E. coli serotypes including O26, O103, O104, O111, O145, and O157 and on other pathogens significant in foodborne diseases, such as Salmonella Typhimurium, Campylobacter jejuni, and Listeria monocytogenes, were also assessed.Materials and Methods:All strains were applied with different amounts of ABS and antimicrobial effect was screened. S. Typhimurium groups were screened for survival using the fluorescence in situ hybridization technique.Results:The relative efficacy of ABS solutions to achieve significant logarithmic reduction in foodborne pathogens E. coli O157:H7 and non-O157 serogroups and other emerging foodborne pathogens is demonstrated in this study. ABS has antibacterial effects.Conclusion:Our present study indicated for the first time that ABS may act against E. coli O157:H7, which is a cause of thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and hemorrhagic colitis. The interrelationships between colitis, infection, and hemostasis within the context of ABS application should be further investigated in future studies.

show abstract

“…The role of topical haemostatic agents in non‐variceal upper GIB is well established, but its use in lower GIB is unclear. There are early data reporting success in conditions such as post‐polypectomy bleeding, angiodysplasia, proctitis and diverticulosis. Topical haemostatic powders are an attractive option in diverticular bleeding as they are non‐thermal, non‐contact and do not require precise targeting on widespread diverticulosis .…”

Section: Introductionmentioning

confidence: 99%

“…There are early data reporting success in conditions such as post‐polypectomy bleeding, angiodysplasia, proctitis and diverticulosis. Topical haemostatic powders are an attractive option in diverticular bleeding as they are non‐thermal, non‐contact and do not require precise targeting on widespread diverticulosis . Despite these advantages, its utility and efficacy in diverticular bleeding with major stigmata of recent haemorrhage (SRH), defined as arterial and venous bleeders, visible vessels and adherent clots, are unknown.…”

Section: Introductionmentioning

confidence: 99%

Topical haemostatic powder as a novel endoscopic therapy for severe colonic diverticular bleeding

Marican

Mathew

2018

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background: Although most diverticular bleeding resolve spontaneously, up to 30% can bleed torrentially, necessitating angioembolization, endoscopic or surgical intervention. Non-contact endoscopic therapies, such as topical haemostatic powders, do not require precise targeting and are attractive because identification of specific culprit diverticulum is difficult. While their use in non-variceal upper gastrointestinal bleeding is well established, its role in lower gastrointestinal bleeding remains unclear. We used topical Hemospray in a novel setting of severe diverticular bleeding, evaluating its efficacy in achieving haemostasis, reducing re-bleeding and the need for re-intervention. Methods: Consecutive patients from a tertiary colorectal unit who underwent colonoscopy and Hemospray for severe diverticular bleeding from November 2016 to October 2017 were included. Hemospray was endoscopically applied to colonic segments with major stigmata of recent haemorrhage. Results: Ten patients had a median time to colonoscopy of 22 h (range: 8-54) from admission. Median of 3.5 units (range: 0-10) of packed cells were transfused pre-endoscopy. All achieved immediate haemostasis without further haemodynamic instability or re-bleeding. No endoscopic, radiological or surgical re-intervention was required. Patients were fit for discharge within a median of 3 days (range: 2-7) following Hemospray. There were no morbidities, mortalities or readmissions for diverticular bleeding after a median follow-up of 9.5 months (range: 3-16).Conclusion: This feasibility study shows that topical haemostatic powders can offer a safe and effective therapeutic endoscopic option in severe diverticular bleeding with high haemostatic rate. Prospective controlled trials are required to establish its efficacy compared to conventional therapy. © 2018 Royal Australasian College of Surgeons ANZ J Surg 89 (2019) E56-E60 ANZJSurg.com © 2018 Royal Australasian College of Surgeons E60Ng et al.

show abstract

The use of Ankaferd in diverticular bleeding: Two case reports

Cited by 9 publications

References 11 publications

Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review

Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

Topical haemostatic powder as a novel endoscopic therapy for severe colonic diverticular bleeding

Contact Info

Product

Resources

About